Anne Kramer

Title: Anne Kramer: Innovator in Chimeric Antigen Receptors

Introduction

Anne Kramer is a prominent inventor based in London, GB. She has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CARs) for cancer treatment. With a total of 2 patents, her work is paving the way for innovative therapies targeting B cell malignancies.

Latest Patents

Kramer's latest patents focus on a chimeric antigen receptor (CAR) that includes a CD19-binding domain. This CAR comprises a heavy chain variable region (VH) with specific complementarity determining regions (CDRs) and a light chain variable region (VL) with its own set of CDRs. The sequences of these CDRs are crucial for the receptor's functionality. Additionally, her patents describe the use of cells containing such CARs in the treatment of cancer, particularly targeting B cell malignancies.

Career Highlights

Throughout her career, Anne Kramer has worked with notable companies such as UCL Business Plc and Autolus Limited. Her experience in these organizations has contributed to her expertise in the field of immunotherapy and biotechnology.

Collaborations

Kramer has collaborated with several professionals in her field, including Martin Pulé and Leila Mekkaoui. These partnerships have enhanced her research and development efforts, leading to innovative solutions in cancer treatment.

Conclusion

Anne Kramer's contributions to the field of chimeric antigen receptors are noteworthy and demonstrate her commitment to advancing cancer therapies. Her innovative work continues to inspire future developments in biotechnology.